CCGs facing 'significant financial risk' after generic drug price surge

By Sharon Brennan2017-12-05T06:00:00

Clinical commissioning groups are facing “significant financial risk” this financial year due to supply issues pushing up the prices they have to pay for generic drugs.

You need to be signed in to read more

Subscribe for unlimited access

With a HSJ subscription you’ll unlock:

All of HSJ.co.uk and our HSJ mobile app
News and insight on all areas of public funded healthcare
Expert commentary, insight and analysis from industry leaders
9 weekly ‘Expert Briefing’ insight emails covering a variety of specialist topics

Alternatively, click here to register for free to keep reading this article and to receive our daily news alerts

to HSJ

Sign into your account here